💼 My Portfolio 👁 Watchlist 🧠 AI Stock Analysis 🤖 AI Portfolio Analysis 📊 Fear & Greed 💬 Community 🔴 Live 📰 Archives 🛒 Shop

← Back to Screener

Evolent Health

EOLS Small Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Updated: May 22, 2026, 22:06 UTC

$6.09
-5.58% today
52W: $3.86 – $10.62
52W Low: $3.86 Position: 33% 52W High: $10.62

Key Metrics

P/E Ratio
—
Price-to-Earnings
Forward P/E
22.84x
Forward Price/Earnings
P/S Ratio
1.33x
Price-to-Sales
EV/EBITDA
—
Enterprise Value/EBITDA
Div. Yield
—
Annual dividend yield
Market Cap
$401.1M
Market Capitalization
Revenue Growth
6.7%
YoY Revenue Growth
Profit Margin
-14.39%
Net profit margin
ROE
—
Return on Equity
Beta
1.29
Market sensitivity
Short Interest
10.24%
% of float sold short
Avg. Volume
1,113,703
Average daily volume

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Strong Buy
6 analysts
Avg. Price Target
$14.67
+140.83% upside
Target Range
$10.00 – $20.00

About the Company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: United States Employees: 350 Exchange: NGM

Evolent Health Stock at a Glance

Evolent Health (EOLS) is currently trading at $6.09 with a market capitalization of $401.1M. The 52-week range spans from $3.86 to $10.62; the current price is 42.7% below the yearly high. Year-over-year revenue growth stands at +6.7%.

💰 Dividend

Evolent Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Evolent Health (EOLS) on consensus: Strong Buy. The average price target is $14.67, implying +140.83% from the current price. Analyst price targets range from $10.00 to $20.00.

Investment Thesis: Strengths & Weaknesses

Strengths
  • High gross margin of 66.05% — indicates pricing power
  • Analyst consensus: Strong Buy
Weaknesses
  • –Currently unprofitable
  • –High short interest (10.24%)
  • –Negative free cash flow

Technical Snapshot

50-Day MA
$5.15
+18.25% vs. price
200-Day MA
$5.95
+2.35% vs. price
Below 52W High
−42.7%
$10.62
Above 52W Low
+57.8%
$3.86

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

Market Risk (Beta)
1.29 · Elevated
Moves more than the overall market
Short Interest
10.24% · High
% of float sold short

The data points to market-like volatility, elevated short interest (10.24%).

Trading Data

50-Day MA: $5.15
200-Day MA: $5.95
Volume: 611,119
Avg. Volume: 1,113,703
Short Ratio: 9.04
P/B Ratio: —
Debt/Equity: —
Free Cash Flow: $-23,226,376

Evolus (EOLS) 2026: 6,50 USD US Performance-Beauty Aesthetic-Medical Specialist with Jeuveau Botulinum-Toxin Plus Evolysse Dermal-Filler Pipeline

The Real Story

Evolus Inc. (NASDAQ: EOLS) is a Newport Beach, California-headquartered performance-beauty company in the cash-pay aesthetic-medical market. Lead products: Jeuveau (proprietary 900-kilodalton purified botulinum-toxin Type A for glabellar lines, marketed in US, Canada, Europe, Australia), Evolysse (dermal-filler pipeline, FDA-pending). Direct-competitor positioning versus Allergan Botox and Revance Daxxify.

What Smart Money Thinks

Evolus has institutional base. BlackRock at approximately 6,4 percent, Vanguard at approximately 5,2 percent. Strathspey Crown historical sponsor. Short-interest sits at approximately 19 percent of float as of May 2026.

Explore the BMI Smart-Money Tracker →

📈 The 3 Real Bull Points

#1 Jeuveau market-share growth versus Botox and Daxxify supports revenue compounding

Jeuveau has captured approximately 14 percent US-aesthetic-botulinum-toxin market-share since 2019 launch, compounding revenue 25-35 percent annually.

#2 Evolysse dermal-filler pipeline creates structural-growth-channel post-2026 FDA approval

Evolysse hyaluronic-acid dermal-filler pipeline (FDA-decision-expected late-2026) opens 2+ billion USD US-dermal-filler-TAM opportunity.

#3 Cash-pay aesthetic market is structurally insurance-independent and defensive

Cash-pay aesthetic-medical market provides structural-insulation from insurance-reimbursement cycles.

📉 The 3 Real Bear Points

#1 Competitive intensity from Allergan Botox, Revance Daxxify, AbbVie aesthetics

Larger competitors compress Jeuveau pricing-power.

#2 Negative book value plus operating burn requires continued capital-raise

Negative book-value plus pre-profit operating burn create dilution risk.

#3 Evolysse FDA-approval execution-risk could delay revenue trajectory

FDA-approval slip would delay revenue-trajectory and compress fair-value.

Valuation in Context

Evolus at 6,50 USD per share with approximately 65,9 million shares outstanding has a market capitalization of approximately 428 million USD. Forward-P/E 24,4x.

Re-rating on Evolysse approval supports 12-16 USD price range — 85-145 percent upside. Bear-case 3-4 USD. Bull-case 18-24 USD.

🗓️ Next 3 Catalyst Dates

  1. 2026 Q3:

    Q2 2026 earnings. Jeuveau growth.

  2. 2026 Q4:

    Evolysse FDA approval decision.

  3. 2027 Q1:

    Fiscal-2026 full-year plus 2027 guidance.

💬 Daniel's Take

Evolus is a aesthetic-medical-specialist with Jeuveau botulinum-toxin growth, Evolysse pipeline-catalyst and cash-pay defensive market. Position-sizing: 0,3–0,8 percent.

Sources (3)

Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.

Where can I buy Evolent Health?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top
WordPress Cookie Notice by Real Cookie Banner